Eton Pharmaceuticals, Inc.
A maker of rare-disease treatments for children and adults, Eton Pharmaceuticals markets FDA-approved products including INCRELEX for growth disorders and ALKINDI SPRINKLE, a first-of-its-kind granular hydrocortisone for kids with adrenal insufficiency. Born in 2017 as a spinoff from Imprimis Pharmaceuticals, the Deer Park, Illinois company reworks existing medicines into friendlier forms—like a needle-free ZENEO autoinjector that blasts an emergency dose through the skin in a fraction of a second.
Bought 587.5K · Sold 1.58M
Sold 1.52M
Bought 50.0K · Sold 430.0K
Bought 10.0K
Sold 41.7K
Granted 134.6K · Bought 5.0K
Bought 8.5K
Bought 5.0K
Granted 112.8K · Sold 159.0K
Bought 10.0K
Granted 50.0K · Sold 50.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% owner · 48 transactions | — | 5.62Mas of Jun 2025 | — | 587.5K | 1.58M |
| Harrow Health, Inc.10% owner · 1 transaction | — | 1.98Mas of Apr 2021 | — | — | 1.52M |
| Brynjelsen SeanPresident & CEO, Director · 21 transactions | — | 961.2K | — | 50.0K | 430.0K |
| Baum Mark LDirector · 1 transaction | — | 794.7Kas of Nov 2018 | — | 10.0K | — |
| Gruber James R.Chief Financial Officer · 4 transactions | — | 213.4K | — | — | 41.7K |
| Riedel Norbert GDirector · 7 transactions | — | 204.6K | 134.6K | 5.0K | — |
| Casamento Charles JDirector · 4 transactions | — | 68.4Kas of Mar 2020 | — | 8.5K | — |
| Maier Paul VDirector · 1 transaction | — | 59.7Kas of Nov 2018 | — | 5.0K | — |
| Krempa DavidChief Business Officer · 17 transactions | — | 37.0K | 112.8K | — | 159.0K |
| Troutman William WilsonCFO, Treasurer & Secretary · 2 transactions | — | 23.0Kas of Aug 2021 | — | 10.0K | — |
| Erdogan-Trinkaus IpekChief Commercial Officer · 1 transaction | — | 2.4K | — | — | — |
| Adams Jennifer McKieDirector · 2 transactions | — | 0 | 50.0K | — | 50.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.10M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.